Clinical Trial Update: Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule [Phase 2]

View source ↗

Summary

Sanofi is conducting a Phase 2 trial of a bispecific nanobody targeting OX40L and TNF for Type 1 Diabetes Mellitus. The study is currently active but not recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Anti-OX40L/Anti-TNF bispecific nanobody (bispecific single-domain antibody targeting OX40L and TNF)

Snippet

Sponsor: Sanofi | Conditions: Type 1 Diabetes Mellitus | Phase 2 | Status: ACTIVE_NOT_RECRUITING